Although in vivo studies are necessary to validate these results, our findings suggests that the Bar + FTI treatment combination might have therapeutic benefits for patients with HGPS-, FPLD2-, and MADB-associated lipodystrophy and possibly other age-related diseases. This evidence concerns the gene ZMPSTE24 and lipodystrophy.